Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cynthia A Bossie

Showing results (1-10 of 63) with videos related to

Pageof 7
Sort By:
Innovations in Clinical Neuroscience|July 15, 2016
ASPECT-R-A Tool to Rate the Pragmatic and Explanatory Characteristics of a Clinical Trial DesignLarry D Alphs, Cynthia A Bossie
Schizophrenia Research|January 21, 2006
Measuring remission in schizophrenia: response to Sethuraman et al., 2005Mary Kujawa, Cynthia A Bossie, Robert A Lasser
The American Journal of Psychiatry|May 2, 2006
New-onset tardive dyskinesia in patients with first-episode psychosis receiving risperidone or haloperidolGeorges M Gharabawi, Cynthia A Bossie, Young Zhu
International Clinical Psychopharmacology|June 8, 2015
Long-acting injectable versus daily oral antipsychotic treatment trials in schizophrenia: pragmatic versus explanatory study designsCynthia A Bossie, Larry D Alphs, Christoph U Correll
International Clinical Psychopharmacology|June 18, 2004
Improvements in stable patients with psychotic disorders switched from oral conventional antipsychotics therapy to long-acting risperidoneJim van Os, Cynthia A Bossie, Robert A Lasser
International Clinical Psychopharmacology|June 4, 2005
Lack of impact of race on the efficacy and safety of long-acting risperidone versus placebo in patients with schizophrenia or schizoaffective disorderNatalie Ciliberto, Cynthia A Bossie, Ronald Urioste, et al.
Neuropsychiatric Disease and Treatment|February 3, 2009
Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophreniaIbrahim Turkoz, Cynthia A Bossie, Bryan Dirks, et al.
International Clinical Psychopharmacology|January 27, 2010
Risperidone long-acting therapy in stable patients with recently diagnosed schizophreniaWayne Macfadden, Cynthia A Bossie, Ibrahim Turkoz, et al.
Innovations in Clinical Neuroscience|May 26, 2016
The Direct and Indirect Effects of Paliperidone Extended-release on Depressive Symptoms in Schizoaffective Disorder: A Path AnalysisIbrahim Turkoz, Dong-Jing Fu, Cynthia A Bossie, et al.
Journal of Psychosocial Nursing and Mental Health Services|November 1, 2019
Long-Acting Injectable AntipsychoticsKaren Johnston, Jennifer Kern Sliwa, Cynthia A Bossie, et al.
Pageof 7

Showing results (1-10 of 63) with videos related to

Sort By:
Pageof 7
Innovations in Clinical Neuroscience|July 15, 2016
ASPECT-R-A Tool to Rate the Pragmatic and Explanatory Characteristics of a Clinical Trial DesignLarry D Alphs, Cynthia A Bossie
Schizophrenia Research|January 21, 2006
Measuring remission in schizophrenia: response to Sethuraman et al., 2005Mary Kujawa, Cynthia A Bossie, Robert A Lasser
The American Journal of Psychiatry|May 2, 2006
New-onset tardive dyskinesia in patients with first-episode psychosis receiving risperidone or haloperidolGeorges M Gharabawi, Cynthia A Bossie, Young Zhu
International Clinical Psychopharmacology|June 8, 2015
Long-acting injectable versus daily oral antipsychotic treatment trials in schizophrenia: pragmatic versus explanatory study designsCynthia A Bossie, Larry D Alphs, Christoph U Correll
International Clinical Psychopharmacology|June 18, 2004
Improvements in stable patients with psychotic disorders switched from oral conventional antipsychotics therapy to long-acting risperidoneJim van Os, Cynthia A Bossie, Robert A Lasser
International Clinical Psychopharmacology|June 4, 2005
Lack of impact of race on the efficacy and safety of long-acting risperidone versus placebo in patients with schizophrenia or schizoaffective disorderNatalie Ciliberto, Cynthia A Bossie, Ronald Urioste, et al.
Neuropsychiatric Disease and Treatment|February 3, 2009
Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophreniaIbrahim Turkoz, Cynthia A Bossie, Bryan Dirks, et al.
International Clinical Psychopharmacology|January 27, 2010
Risperidone long-acting therapy in stable patients with recently diagnosed schizophreniaWayne Macfadden, Cynthia A Bossie, Ibrahim Turkoz, et al.
Innovations in Clinical Neuroscience|May 26, 2016
The Direct and Indirect Effects of Paliperidone Extended-release on Depressive Symptoms in Schizoaffective Disorder: A Path AnalysisIbrahim Turkoz, Dong-Jing Fu, Cynthia A Bossie, et al.
Journal of Psychosocial Nursing and Mental Health Services|November 1, 2019
Long-Acting Injectable AntipsychoticsKaren Johnston, Jennifer Kern Sliwa, Cynthia A Bossie, et al.
Pageof 7